Abstract
Objectives This study aims to describe a specific system of reimbursement of highly innovative drugs (HID) in the Czech Republic, representing a time-limited reimbursement under special conditions. The second objective is to evaluate the total number of drugs approved as HID, as well as the number of drugs entering or failing to enter the system of regular reimbursement. The third objective is to describe the development of costs and impact of HID on the overall public pharmaceutical expenditures.
Highlights
Growing unmet need in treatment of very severe and rare diseases is enhancing a development of new innovative drugs
This study aims to describe a specific system of reimbursement of highly innovative drugs (HID) in the Czech Republic, representing a time-limited reimbursement under special conditions
There were 52 drugs approved as HID during 2008-2015, with 21 already having entered the system of regular reimbursement
Summary
Growing unmet need in treatment of very severe and rare diseases is enhancing a development of new innovative drugs. The inclusion of these drugs in the reimbursement system is becoming a critical issue in many countries, as most of them prove their clinical and cost effectiveness just partly at the time of submission
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
